CoChat
Sign Up
Cited by 122Lung Cancer Treatments and MutationsCancer survivorship and careHealth Systems, Economic Evaluations, Quality of Life

The DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)

Open access
Chen, G., Feng, J., Zhou, C., Wu, Y.-L., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., Lu, S., Zhang, L., Hu, C.-P., Hu, C., Luo, Y., Chen, L., Ye, M., Huang, J., Zhi, X., Zhang, Y., Xiu, Q., Ma, J., Zhang, L., You, C.·2013·Annals of Oncology
DOI 10.1093/annonc/mdt012
Open this paper in CoChat — free account

Abstract

Background The OPTIMAL study found that erlotinib improved progression-free survival (PFS) versus standard chemotherapy in Chinese patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). This report describes the quality of life (QoL) and updated PFS analyses from this study.Patients and methods Chinese patients ≥ 18 years with histologically confirmed stage IIIB or IV NSCLC and a confirmed activating mutation of EGFR (exon 19 deletion or exon 21 L858R point mutation) received erlotinib (150 mg/day; n = 82) or gemcitabine-carboplatin (n = 72). The primary efficacy end point was PFS; QoL was assessed using the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire, Trial Outcome Index (TOI) and Lung Cancer Subscale (LCS).Results Patients receiving erlotinib experienced clinically relevant improvements in QoL compared with the chemotherapy group in total FACT-L, TOI and LCS (P < 0.0001 for all scales). Erlotinib scored better than chemotherapy for all FACT-L subscales from baseline to cycles 2 and 4 (non-significant). In the updated analysis, PFS was significantly longer for erlotinib than chemotherapy (median PFS 13.7 versus 4.6 months; HR = 0.164, 95% CI = 0.105-0.256; P < 0.0001), which was similar to the previously reported primary analysis.Conclusion Erlotinib improves QoL compared with standard chemotherapy in the first-line treatment of patients with EGFR mutation-positive advanced NSCLC.

Overview

Integrity signals

Registry

Crossref · 10.1093/annonc/mdt012

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 21 references

Cited by

Sorted by citations

Items 101–122 of 122

Related

See all

Metadata

Authors
Chen, G., Feng, J., Zhou, C., Wu, Y.-L., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., Lu, S., Zhang, L., Hu, C.-P., Hu, C., Luo, Y., Chen, L., Ye, M., Huang, J., Zhi, X., Zhang, Y., Xiu, Q., Ma, J., Zhang, L., & You, C.
Affiliations
  • Harbin Medical University (CN)
  • Jiangsu Cancer Hospital (CN)
  • Tongji University (CN)
  • Guangdong General Hospital (CN)
  • Academy of Military Medical Sciences (CN)
  • Tianjin Medical University Cancer Institute and Hospital (CN)
  • Capital Medical University (CN)
  • Peking University Cancer Hospital (CN)
  • Shanghai Jiao Tong University (CN)
  • Hunan Cancer Hospital (CN)
  • Cancer Hospital of Shantou University Medical College (CN)
  • First Affiliated Hospital of Soochow University (CN)
  • Zhejiang Cancer Hospital (CN)
  • Second Military Medical University (CN)
  • Nanfang Hospital (CN)
Corresponding author
Zhou, C.
ORCID
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2013-06
Volume
24
Issue
6
Pages
1615-1622
ISSN
0923-7534 (ISSN-L)
DOI
10.1093/annonc/mdt012
OpenAlex
W2165771694
Cited by
121
References
21
Citations by year
2026: 2 · 2025: 1 · 2024: 7 · 2023: 2 · 2022: 5 · 2021: 11 · 2020: 6 · 2019: 11 · 2018: 9 · 2017: 9 · 2016: 15 · 2015: 19 · 2014: 13 · 2013: 10
FWCI
15.44
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • the Shanghai Pulmonary Hospital and the Chinese Thoracic Oncology Group
  • F. Hoffmann-La Roche
  • the Science and Technology Commission of Shanghai Municipality (06DZ19502)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords
erlotinib, EGFR-mutant non-small cell lung cancer, quality of life, first-line therapy, progression-free survival, Chinese patients, exon 19 deletion, L858R mutation
MeSH terms
Erlotinib Hydrochloride, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Follow-Up Studies, Humans, Male, Middle Aged, Mutation, Quality of Life, Surveys and Questionnaires, Quinazolines, Disease-Free Survival, Protein Kinase Inhibitors, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review